Form 4 Filing for Amylyx Pharmaceuticals, Inc. - Officer/Director Transaction

This filing details a Form 4 submission for Amylyx Pharmaceuticals, Inc. (AMLX), reporting a transaction by Director Karen Firestone. On June 4, 2026, Ms. Firestone was granted 24,372 stock options for the company's Common Stock, with an exercise price of $14.31 per share. These options are exercisable and will vest in full on the earlier of June 4, 2027, or the next annual meeting, contingent upon Ms. Firestone's continuous service to the Issuer. The options have an expiration date of June 3, 2036. This transaction is classified as an acquisition of securities.